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1  | HISTORIC AL TIMELINE—THE 
WARBURG EFFEC T THEN AND NOW
In the early 20s of the last century, Warburg, Posener, and 
Negelein1 discovered a unique behavior of tumor tissue in vitro. 
They examined respiration and glycolysis of different tissue sec-
tions and found that tumors exhibit an unusually high glycolytic 
activity and production of lactic acid from glucose when com-
pared with normal tissues. Surprisingly, glycolysis was “aerobic” 
and was not inhibited by oxygen in malignant cells meaning that 
cancer cells lack the “Pasteur effect.” Carl F. Cori and Gerty Cori 
confirmed this finding in living animals. Interestingly, the lactic 
acid content of tumors was low in starving animals with low-glu-
cose levels and the authors concluded “up to a certain limit an 
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Abstract
The “glycolytic switch” also known as the “Warburg effect” is a key feature of tumor 
cells and leads to the accumulation of lactate and protons in the tumor environment. 
Intriguingly, non-malignant lymphocytes or stromal cells such as tumor-associated 
macrophages and cancer-associated fibroblasts contribute to the lactate accumula-
tion in the tumor environment, a phenomenon described as the “Reverse Warburg 
effect.” Localized lactic acidosis has a strong immunosuppressive effect and mediates 
an immune escape of tumors. However, some tumors do not display the Warburg 
phenotype and either rely on respiration or appear as a mosaic of cells with differ-
ent metabolic properties. Based on these findings and on the knowledge that T cell 
infiltration is predictive for patient outcome, we suggest a metabolic-tumor-stroma 
score to determine the likelihood of a successful anti-tumor immune response: (a) a 
respiring tumor with high T cell infiltration (“hot”); (b) a reverse Warburg type with 
respiring tumor cells but glycolytic stromal cells; (c) a mixed type with glycolytic and 
respiring compartments; and (d) a glycolytic (Warburg) tumor with low T cell infiltra-
tion (“cold”). Here, we provide evidence that these types can be independent of the 
organ of origin, prognostically relevant and might help select the appropriate immu-
notherapy approach.
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excess of lactic acid can be completely eliminated into the blood 
stream.” In another set of experiments, the Cori laboratory com-
pared blood that had passed through a tumor with normal venous 
blood in chicken and observed decreased sugar and increased lac-
tic acid in blood from the tumor-bearing wing.2,3 In 1926, Otto 
Warburg further analyzed the energy metabolism of tumors and 
discussed possible ways to kill tumor cells through a “lack of en-
ergy”.4 Warburg measured glucose and lactic acid in tumor arter-
ies and veins and found greater differences than the Coris. His 
results showed that the concentration of glucose falls by about 
57% after passing through a tumor, whereas normal tissues con-
sume about 2%-18% of the arterial glucose. Tumor veins con-
tained clearly more lactic acid than arteries, but this was not the 
case for normal tissues. He stated that tumor cells obtain energy 
in two ways, by respiration and fermentation and calculated that 
about 66% of the glucose is used in fermentation and the rest for 
respiration, but this may vary in different parts of the tumor based 
on heterogeneity in glucose and oxygen availability. He concluded 
that “it is necessary to stop both respiration and fermentation, 
if cells are to be killed for want of energy”.5 Later in his life, he 
changed his side of view and claimed that tumor cells are charac-
terized by a damaged respiration.6,7
In contrast to these observations and numerous studies since, 
two recent publications stated that the tumor environment con-
tains no elevated lactate levels in the interstitial fluid,8,9 and lac-
tate may accumulate preferentially in tumor cells. In this case, the 
tumor stroma, for example, immune cells, would not face high-lac-
tate concentrations. However, Sullivan and colleagues examined 
pancreatic ductal adenocarcinoma (PDAC), a tumor with high stro-
mal/fibroblast content. A possible explanation for low lactate lev-
els in this tumor model is a metabolic symbiosis in heterogeneous 
tumors consisting of fibroblasts and highly glycolytic tumor cells. 
Here, tumor cells produce and secrete lactate which is consumed 
and used as a fuel for respiration by adjacent stromal cells.10,11 
Alternatively, it has been shown by Sonveaux and colleagues that 
respiring tumor cells in oxygenated regions take up lactate and 
metabolize it.12 Low lactate levels may also occur in tumors where 
lactate is eliminated by the blood stream in well-perfused tumor 
regions. But compromised blood perfusion is a typical feature of 
tumors and may help to build up extracellular levels of lactate and 
protons in the tumor environment especially in tumors with highly 
accelerated glycolysis. In tumors with extremely high glycolytic ac-
tivity, elevated lactate levels can also be detected in sera of tumor 
patients.13,14 Accordingly, lactate levels have been suggested as 
a prognostic biomarker in high-grade primary brain tumors and 
metastatic lung cancer where elevated pretreatment serum lactate 
levels were associated with worse progression free survival.15,16 
Bringing an additional layer of complexity, in the “Reverse Warburg 
Effect” stromal cells such as fibroblasts or macrophages undergo 
“aerobic glycolysis” and produce lactic acid which can either ac-
cumulate or be utilized by cancer cells for mitochondrial oxidative 
phosphorylation (OXPHOS).17-19 Thus, not only malignant cells but 
also stromal cells contribute to tumor lactic acidosis. Furthermore, 
acidosis is not only associated with lactic acid secretion, as an-
other major source of protons is CO2, produced in more oxygen-
ated tumor areas which is hydrated into HCO3− and H+ ions by 
carbonic anhydrases leading to acidification.20
Today, we know that tumors often represent a mosaic of tumor 
cells with different metabolic properties. While some tumors rely 
more on oxygen, others can be more glycolytic. Metabolic hetero-
geneity regarding glucose metabolism within and between human 
lung tumors was nicely demonstrated by the group of DeBerardinis 
using intraoperative 13C-glucose infusions in patients.21 The au-
thors concluded that enhanced glucose uptake by lung tumors 
supplies glucose oxidation rather than enhanced lactate fermenta-
tion. On the other hand, in vivo isotope tracing in human clear cell 
renal cell carcinomas (ccRCC) revealed enhanced glycolysis and 
minimal glucose oxidation compared to adjacent kidney consistent 
with the classical Warburg phenotype.22 A metabolic heterogene-
ity among ccRCC tumors was demonstrated by Brooks et al with 
low or no 18F fluoro-deoxy-glucose (FDG) uptake in some tumors 
but uniformly high uptake in other tumors.23 We studied T cell 
infiltration in relation to tumor glucose transporter 1 (GLUT1) ex-
pression in ccRCC and identified two major tumor types. Classical 
Warburg tumors with high GLUT1 expression and low T cell infil-
tration, and tumors with low tumor GLUT1 expression and high 
T cell infiltration in the tumor (Figures 1 and 2).24 In line a recent 
publication described a negative correlation between increased 
glycolysis and CD8 T cell infiltration in colon cancer.25 What is 
more, GLUT1 expression inversely correlated with numbers of 
CD3+ T cells in HNSCC and lung SCC.26
Two molecular subgroups with low- and high OXPHOS were 
also identified in high-grade serous ovarian cancer. While low-OX-
PHOS tumors mainly exhibit a glycolytic metabolism, high-OX-
PHOS tumors rely on oxidative phosphorylation supported by 
glutamine and fatty acid oxidation. Furthermore, distinct met-
abolic subtypes were described in PDAC cell line models. Here, 
lipogenic tumor cell lines showed higher oxygen consumption and 
greater mitochondrial content compared with glycolytic tumor 
lines. In primary pancreatic tumor samples, the lipid subtype was 
strongly associated with an epithelial phenotype, whereas the gly-
colytic subtype was associated with a mesenchymal phenotype.27 
Based on the negative correlation between glycolytic activity, 
GLUT expression and T cell infiltration, these data suggest a stron-
ger immune cell infiltration in high-OXPHOS tumors compared to 
tumors with glycolytic activity in ovarian and pancreatic cancer 
(Figure 1).
These data also implicate that the “Warburg phenotype” is not 
characteristic for all tumor entities and not even for all tumor cells 
within one given tumor. Nevertheless, the work of Otto Warburg 
and colleagues has an enormous impact on current cancer research 
and diagnostics. Uptake of the positron-labeled glucose analogue 
18F-fluoro-deoxy-glucose determined with positron emission to-
mography (18F-FDG-PET) is a well-established method for tumor 
diagnosis and staging. Even disseminated and hematologic ma-
lignancies, such as lymphoma can be imaged by FDG-PET,28,29 
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demonstrating that not only solid tumors but also leukemia and lym-
phoma cells of different origin display an accelerated glucose me-
tabolism, which was confirmed by gene expression and functional 
analysis.30-32 Moreover, the discovery that oncogenes and tumor 
suppressor genes are closely linked to and regulate the Warburg ef-
fect has led to a renewed interest in tumor metabolism which is now 
regarded as a hallmark of cancer.33
2  | WARBURG EFFEC T IN TUMOR 
STROMAL CELL S
The observed composition of tumors regarding both a cellular and 
a metabolic heterogeneity lead us to propose the metabolic-tumor-
stroma score (MeTS) with following subtypes: (MeTS1) a respiring 
tumor type; (MeTS2) a reverse Warburg type with respiring tumor 
cells but glycolytic stromal cells; (MeTS3) a mixed type with both 
glycolytic and respiring cells; and (MeTS4) a glycolytic (Warburg) 
tumor (Figure 1). High metabolic heterogeneity puts into question 
whether the PET signal is related to glucose metabolism of tumor 
cells, stromal cells or both and to what extent in which tumor entity. 
A shift in energy metabolism toward aerobic glycolysis is not only 
a hallmark of cancer cells but also of activated immune cells. Here, 
aerobic glycolysis is discussed as a prerequisite for T and NK cell ef-
fector functions.34-39 Moreover, high glycolytic activity is associated 
with myeloid cell activation as shown for monocytes, macrophages 
and dendritic cells (DCs).40-42 TLR signaling promotes glycolysis and 
leads to a decline in OXPHOS.43,44 Thus, 18F-FDG can be taken up 
by glycolytic inflammatory cells and has been reported to accumulate 
in acute and chronic inflammatory lesions, granulomatous diseases, 
and autoimmune diseases. Accordingly, tumor-infiltrating immune 
cells are also able to take up 18F-FDG and it has been shown that 
high uptake of 18F-FDG by inflammatory cells is a frequent cause 
of false positive results in 18F-FDG-PET.45 However, it is difficult to 
differentiate viable tumor cells from tumor-infiltrating immune cells 
and similarly, to distinguish lymph node metastases from immune ac-
tivation in reactive lymph nodes.46,47 A clinical correlate of increased 
activity of immune cells in tumors is the phenomenon of pseudo-pro-
gression. Tumor pseudo-progression describes an apparent tumor 
growth after immunotherapy and might be explained by increased 
tumoral inflammation after immune cell re-activation. Even though 
challenging for patients and clinicians, tumor pseudo-progression in 
a computer tomography (CT) scan or 18F-FDG-PET might precede a 
good clinical response to immunotherapy.48 Importantly, the immune 
activity can emit PET signals similar to those from tumors, and there-
fore, 18F-FDG-PET cannot differentiate a true progression from a 
F I G U R E  1   A metabolic-tumor-stroma score (MeTS) to describe the tumor metabolic and cellular heterogeneity and to assess the quality 
of anti-tumor immune response
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pseudo-progression.49,50 Cancer-associated fibroblasts (CAFs) can 
account for a high proportion of the tumor stroma and can contrib-
ute to the uptake of 18F-FDG. Shangguan et al51 analyzed the as-
sociation of CAFs with 18F-FDG signals in colon cancer and showed 
that CAFs density correlated with the standardized uptake value.
In a small cohort of patients, we analyzed stroma-rich tumors for 
GLUT1 and CD3 expression by immunohistochemistry and detected 
GLUT1 positive CAFs in a pancreatic carcinoma patient, however, 
only in a subset of stromal cells (MeTS2a, Figure 3). In colon carci-
noma and mammary carcinoma tissues, CAFs were mainly GLUT1 
negative and these areas were often highly infiltrated by CD3-
positive T cells (MeTS3a, Figure 3).
In light of these observations, high 18F-FDG uptake can also 
reflect an intense ongoing host reaction, such as after radiation 
therapy, where 18F-FDG uptake by tumor tissues is often increased 
despite the decreased viability of tumor cells. In an interesting study, 
Mamede and colleagues analyzed the distribution of 18F-FDG in im-
munocompetent and immunodeficient mice bearing the same mu-
rine ovarian squamous cell carcinoma. Despite comparable tumor 
growth and histology in both mice strains, the 18F-FDG signals were 
significantly higher in tumors in immunocompetent than in immuno-
deficient mice.46 Thus, it was unlikely the tumor metabolic activity, 
but rather an immune activation that led to the increased 18F-FDG 
uptake.46,52,53 In a murine mammary carcinoma model, 18F-FDG ac-
cumulation was even higher in macrophages in the outer zones of 
necrosis than in tumor cells,54 in line with data from Seth et al who 
demonstrated that tumor-associated macrophages (TAMs) produce 
high amounts of lactate which in turn support tumor growth.17 These 
tumors would classify as a reverse Warburg (MeTS2) type with re-
spiring tumor cells but glycolytic stromal cells. Recently, Jeong 
et al nicely showed a positive correlation between CD68+ TAMs and 
18F-FDG uptake in NSCLC patients. Depletion of TAMs in a murine 
model diminished 18F-FDG uptake of tumors and improved T cell in-
filtration.55 These data strongly indicate that high glycolytic activity 
not only in tumor but also in stromal cells such as TAMs can impair 
immune cell function.
The metabolic heterogeneity of tumors extends beyond different 
populations having different metabolic requirements and tumor cells 
show various metabolic interactions with stromal cells. For exam-
ple, it has been shown in pancreas cancer, that tumor cell-produced 
F I G U R E  2   GLUT1 expression and 
CD8 T cell infiltration in clear cell renal 
cell carcinoma (ccRCC). Shown are tissue 
microarrays of two ccRCC patients. 
Patient 1 displays ubiquitous GLUT1 
expression in the tumor tissue while 
lacking CD8 T cell infiltration. Patient 
2 shows low tumor GLUT1 expression 
and high CD8 T cell infiltration. Figure 
adapted from (Singer et al 201124) with a 
permission from the publisher
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lactate can be taken up by CAFs, which in turn produce alpha-keto-
glutarate, leading to TET activation and subsequent decreased cyto-
sine methylation and overexpression of CAFs inflammatory genes.56 
In breast cancer, tumor cell-produced lactate can be taken up and 
used by mesenchymal stroma cells and CAFs as an energy source.57 
On the other hand, CAFs are able to drive glycolysis in tumor cells—
Kumar et al showed that CAF-secreted hepatocyte growth factor 
(HGF) induces tumor cell glycolysis and secretion of basic fibroblast 
growth factor (bFGF). Interestingly, bFGF induces OXPHOS in CAFs, 
leading to HGF production, thus closing the vicious circle.58 In a clin-
ical study, breast cancer patients with stage 0/1 tumors were treated 
with N-acetylcysteine (NAC) to reduce oxidative stress in stromal 
cells and decrease tumor growth. Interestingly, post-treatment biop-
sies showed that stromal (but not tumor) cells decreased expression 
of the lactate exporter MCT4 as a result of NAC treatment, while the 
proliferative index of tumor cells was reduced.59
These studies confirm that tumors are heterogeneous, and high 
glucose uptake is not necessarily a proxy for tumor cell viability and 
proliferation but activated immune cells and other stromal cells such 
as fibroblasts and macrophages can contribute. Therefore, glucose and 
lactate levels in the tumor microenvironment can depend (a) on the 
tumor metabolic type, (b) on the relative percentage of tumor-infiltrat-
ing cells such as immune cells, their type, and activation status, and (c) 
on the type and quantity of stromal cells, such as fibroblasts (Figure 1).
3  | MOLECUL AR BACKGROUND OF 
THE WARBURG EFFEC T IN TUMOR AND 
STROMAL CELL S
Warburg proposed that cancer is caused by a metabolic “switch” 
from mitochondrial respiration to aerobic glycolysis. However, in 
following years numerous groups provided evidence of the impor-
tant role of respiration for tumor growth in several preclinical mod-
els and human tumor entities. We know that cancer development is 
caused by genetic alterations and signaling networks downstream 
F I G U R E  3   Representative images from three tumor entities correlating high glucose metabolism in tumor or stromal cells with T cell 
infiltration. HE staining of primary resected carcinoma of the pancreas (column 1,2), the breast (column 3), and the colon (column 4,5) 
without any neoadjuvant treatment (original magnification column 1: 133x, column 2, 3: 114x, column 4: 153x, column 5: 91x) and the 
corresponding immunhistochemical staining of GLUT1 (middle row) and CD3 (lower row). Higher magnification of the marked areas is shown 
in the lower part. The cancer-associated fibroblasts in pancreatic carcinoma are GLUT1-positive (*) with almost no CD3-positive T cells (**) in 
the stroma. The breast cancer sample shows a strong staining for GLUT1 (+), while CD3-positive T cells are exclusively located in the GLUT1-
negative stroma (++). MeTS 2a,3a,3b: suggested scoring of the tumor-stroma metabolic interaction with infiltrating immune cells
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of oncogenes and tumor suppressors converge to adapt tumor cell 
metabolism.60,61
Mutations in the tricarboxylic citrate acid cycle enzymes succi-
nate dehydrogenase and fumarate hydratase have been identified 
in a limited number of cancers. As a consequence, a dysfunction 
of OXPHOS can induce the Warburg effect in tumor cells. Due to 
these mutations, succinate and fumarate accumulate in mitochon-
dria and also leak out to the cytosol. They inhibit prolyl hydroxylase 
enzymes leading to a pseudo-hypoxic response conveyed by hy-
poxia-inducible factors (HIF) that enhance glycolysis.62 In addition, 
alterations in mitochondrial DNA have been reported in some types 
of cancer, but their functional relevance and contribution to car-
cinogenesis is discussed controversially. Mitochondria are needed 
as synthetic organelles to supply components for the generation of 
nucleic acids, proteins and phospholipids; thus, tumor cells might 
not be able to tolerate defective mitochondria in the long run.63 In 
line, Baker et al64 demonstrated that mitochondrial DNA mutations 
are increased in number in early colon dysplasia but seem to be 
negatively selected in the further course of cancer development.
The catalytic subunit of the mitochondrial H+-ATP complex 
(β-F1-ATPase) is central for ATP synthesis during OXPHOS and in-
tegrates bioenergetic and death-signaling functions of mitochon-
dria. In line with the established role of mitochondrial dysfunction 
in cancer, β-F1-ATPase is often downregulated in tumors com-
pared to healthy tissues. The group of Cuezva reported a repres-
sion of β-F1-ATPase in kidney, colon and breast carcinomas.65,66 
Moreover, some carcinomas upregulate the ATPase inhibitory fac-
tor 1, which inhibits the activity of the H+-ATP synthase.67 This 
is of special importance for chemotherapy as downregulation of 
mitochondrial ATP synthase is associated with drug resistance 
linking the success of anti-cancer therapy to the (dys)function of 
mitochondria.68
Genetic alteration or loss of p53, one of the most frequently 
mutated genes in cancer, also modulates the balance between res-
piration and glycolysis. p53-deficient cells show decreased oxygen 
consumption and increased lactate production.69 Oncogenic trans-
formation does not only decrease the mitochondrial activity of 
tumor cells but can directly accelerate glycolysis. For example, cells 
lacking the tumor suppressor PTEN exhibit a glycolytic phenotype 
reminiscent of the Warburg effect. This has been attributed to the 
hyperactivation of PI3K/AKT signaling as constitutive AKT activ-
ity accelerates glucose uptake and stimulates aerobic glycolysis in 
transformed cells.70 In addition, the loss of PTEN leads to a stabiliza-
tion of 6-phosphofructo-2-kinase (PFKFB3) and increases synthesis 
of its product fructose-2,6-bisphosphate.71 PFKFB3 has been shown 
to be highly expressed and active in human cancer cells and fruc-
tose-2,6-bisphosphate is a key regulator of the glycolytic enzyme 
phosphofructokinase-1. Selective inhibition of PFKFB3 in HCT-116 
colon adenocarcinoma cells causes a marked decrease in glucose 
uptake simultaneously with an increase in autophagy.72 Chronic in-
flammation can promote tumorigenesis and it has been shown that 
pro-inflammatory cytokines such as TNFα and IL-17 stimulate glycol-
ysis in colorectal cancer cells.73
Dysregulated expression of the MYC oncogene occurs in about 
30% of human cancers and MYC overexpression induces mitochon-
drial glutaminolysis and triggers upregulation of glycolytic enzymes, 
like lactate dehydrogenase (LDH) A.74 Oncogenic MYC also interacts 
with HIFs. Hypoxia is characteristic for the tumor milieu as a result 
of decreased tissue microcirculation. HIFs are stabilized in response 
to hypoxia and induce the transcription of more than 70 genes via 
hypoxia response elements, among them genes involved in glucose 
metabolism like GLUT1, LDH or the monocarboxylate transporter 4 
(MCT4) involved in lactate transport.75,76 But even under normoxic 
conditions accumulation of the glycolytic products lactate and pyru-
vate can promote HIF-1 protein stability and regulate gene expres-
sion.77 Acidosis enables HIF to evade destruction in the presence 
of oxygen as low pH elicits a transient and reversible loss of von 
Hippel-Lindau (VHL) function by promoting its nucleolar seques-
tration.78 In summary, HIF activation and stabilization is not only 
a result of hypoxic conditions but is also achieved under normoxia 
through low pH, lactate or pyruvate.
Hypoxia and acidification also suppress the circadian clock 
through diminished translation of clock constituents,79 adding an-
other level of complexity to the metabolic regulation. Clock genes 
control the circadian rhythm in mammalian cells and epidemiological 
studies indicate that disruption of the circadian clock and decreased 
expression of the clock components BMAL1 and PER2 contribute 
to tumorigenesis. PER2 promotes p53 function, while BMAL1 ex-
pression is suppressed by MYC, suggesting bidirectional interac-
tions between clock proteins and key oncogenic regulators of tumor 
metabolism.80
Overall, a complex network of transcriptional regulators controls 
tumorigenesis and metabolism. Even though metabolic reprogram-
ming may result from different driver mutations, it appears that 
recurrent master regulators ultimately lead to common metabolic 
phenotypes across multiple tumor entities. Accordingly, Peng and 
colleagues analyzed TCGA samples across 33 cancer types and 
characterized metabolic tumor subtypes. Master regulators of car-
bohydrate and nucleotide metabolism showed consistently poor 
prognostic patterns across all analyzed cancer types whereas lipid 
metabolism showed the opposite association.81 Accordingly, the ex-
pression of enzymes and transporters involved in glucose metab-
olism has been linked to unfavorable patient outcome in different 
tumor entities such as hepatocellular carcinoma,82,83 melanoma84,85 
or urothelial carcinoma.86 Moreover, in oral squamous cell carcinoma 
a high PET signal, thus a high glucose uptake, correlates with worse 
prognosis83 and similarly, high intra-tumoral lactate concentration 
predicts the occurrence of metastases and patient survival.87,88 
Thus, the phenomenon of lactate accumulation and acidification in 
solid tumors is not simply a surrogate for hypoxia but is the result of 
an interplay of different transcriptional master regulators and, im-
portantly, determines patient outcome.
Similar transcriptional networks and key players such as HIFs 
and MYC described in cancer cells regulate metabolism in immune 
cells and CAFs. Specific deletion of HIF-1α in CAFs reduced VEGF 
production, angiogenesis and reduced myeloid infiltration which in 
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turn restricted tumor growth.89 Moreover, HIF alters the function of 
myeloid derived suppressor cells (MDSCs) in the tumor microenvi-
ronment and redirects their differentiation to TAMs hence providing 
a mechanistic link between different myeloid suppressive cells in 
the tumor microenvironment.90 In addition, HIF-1α selectively up-
regulates PD-L1 on MDSCs, but not other B7 family members and 
blockade of PD-L1 abrogates MDSC-mediated T cell suppression.91 
In macrophages, tumor-conditioned media with high-lactate levels 
stabilized HIF-1α protein under normoxic conditions. HIF induced 
M2-polarization in TAMs and increased VEGF and arginase 1 ex-
pression, which play an important role in regulating tumor growth. 
Collectively, these findings identify a mechanism of communication 
between macrophages and tumor cells via lactate which may have 
evolved to promote tumor growth.92 These data also suggest that 
tumor-derived lactate can determine the suppressive phenotype of 
different myeloid tumor-associated cell populations. A role for HIF 
proteins has also been discussed in lymphoid cells as their activa-
tion stabilizes HIF proteins.93,94 Cho et al show an important role for 
both, HIF-1α and HIF-2α, in triggering cytokine response and for the 
induction of antigen specific B cells by CD4 T cells. Moreover, HIF-1α 
is involved in CD4 Th17 polarization95 and important for the cyto-
lytic function of CD8 T cells.96,97 In contrast, Wang et al94 described 
no apparent phenotype deleting HIF-1α, but the deletion of c-MYC 
impaired T cell activation. In line, c-MYC increased the expression 
of genes related to glucose and glutamine metabolism in T cells.98 
Furthermore, MYC upregulation has been reported in macrophages 
associated with a M2-like phenotype and was detected in human 
TAMs. In line, in vitro alternative polarization of macrophages re-
quires the transcription factor c-MYC.99
In summary, the same signaling pathways are essential for the 
metabolic regulation in immune cells and tumor cells. However, in 
tumor cells oncogenic regulation of these pathways results in a sta-
ble phenotype, whereas immune cells show a transient metabolic 
reprogramming in response to activation or environmental factors.
4  | E VOLUTION OF THE WARBURG 
EFFEC T—BENEFITS FOR THE TUMOR
In 2004, Gatenby and Gillies asked “why do cancers have high 
aerobic glycolysis?”100 and proposed that “cell populations with 
upregulated glycolysis and acid resistance have a powerful growth 
advantage, which promotes proliferation and invasion.” However, 
the metabolism of glucose to lactate is less efficient compared to 
oxidative phosphorylation, at least in terms of ATP production per 
mol of glucose. Why would a proliferating cell use a less efficient 
metabolism? A possible explanation is that proliferating cells have 
requirements that extend beyond ATP as they need to replicate all 
of its cellular contents such as nucleotides, amino acids, and lipids. 
Vander Heiden and colleagues proposed that "the metabolism of 
cancer cells, and indeed all proliferating cells, is adapted to facilitate 
the uptake and incorporation of nutrients into the biomass needed 
to produce a new cell”.101 Would this explain why the Warburg 
effect provides an evolutionary benefit for tumor cells? The excess 
lactate secretion that accompanies the Warburg effect leads to a 
loss of three carbons that could be utilized for building blocks or ATP 
production—an inefficient use of resources. In a more recent publi-
cation, the Vander Heiden group investigated the fraction of carbon 
mass in cells derived from different nutrients and found that the ma-
jority of carbon mass is not derived from glucose but rather from 
glutamine indicating that high glycolysis supports cell proliferation 
through mechanisms beyond providing carbon for biosynthesis.102
Alongside its role in providing carbon for building blocks and en-
ergy generation, aerobic glycolysis results in a high rate of lactate 
production. The maintenance of the glycolytic flux requires a con-
tinuous export of lactate and protons from the cancer cell, which is 
carried out by MCTs. As a result, lactate and protons accumulate in 
the tumor environment resulting in acidification of the extracellular 
space. Acidification is a well-known feature of the tumor environ-
ment and can sustain tumor growth by promoting local invasion, 
metastasis, and inhibiting anti-tumor immunity. Gatenby et al100 pro-
posed an “acid-mediated tumor invasion model” where an altered 
glucose metabolism leads to acidification of the tumor milieu which 
in turn allows tumor cells to form invasive cancers. In line, low extra-
cellular pH promotes metastasis in a human melanoma model103 and 
buffering with bicarbonate prevented acidosis and reduced the for-
mation of spontaneous metastasis.104 Accordingly, Mueller-Klieser 
and colleagues have nicely shown that high-lactate levels in the pri-
mary lesion of human tumors correlate with the incidence of distant 
metastases.87,88 Therefore, the glycolytic phenotype of tumor cells 
appears to facilitate tumor invasion and metastatic spread.
Another integral factor of sustained tumor growth and metasta-
sis is angiogenesis. Tumor-derived lactate can induce vessel forma-
tion through stimulation of VEGF production by endothelial cells.105 
Vegran et al106 have shown, that endothelial cells take up lactate 
through MCT1, resulting in nuclear factor κB activation, expression 
of IL-8, induction of IL-8-dependent angiogenesis and tumor growth. 
In addition to the generally accepted mechanism of tumor vascu-
larization through sprouting of endothelial cells from pre-existing 
vessels, some studies suggest a contribution of stem cell-derived 
endothelial progenitors as well as cells from the myeloid lineage. We 
found that incubation of tumor-associated DCs with pro-angiogenic 
factors, such as vascular endothelial growth factor and oncostatin 
M, led to trans-differentiation of DCs into endothelial-like cells.107
5  | IMMUNOLOGIC AL CONSEQUENCES 
OF THE WARBURG EFFEC T—A METABOLIC 
IMMUNE CHECKPOINT
Several publications underline the importance of immune cell infil-
tration for patient outcome. Galon and colleagues suggested in 2006 
that the type, density, and location of immune cells within colorec-
tal tumor samples are a better predictor of patient survival than 
classical histopathological methods.108 We and others have shown 
that tumor-derived lactate strongly inhibits both T cell and NK cell 
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function14,84,109 and the differentiation and activation of myeloid 
cells.110,111 This indicates that the tumor-promoting effect of lactate 
and acidification may in part be related to its immunosuppressive 
function and the metabolic phenotype of tumors may be decisive for 
T cell activity and thereby for patient prognosis.
Myeloid cells such as MDSCs and TAMs are regarded as important 
regulators of the tumor environment and perform key homeostatic 
functions that allow tumor maintenance and growth. Concordant 
with the hypothesis that lactate modulates myeloid effector func-
tions, Husain et al112 described a decrease in the frequency of 
MDSCs in the spleens of mice carrying Ldh-a depleted tumors in-
dicating that lactate promotes MDSC differentiation. Furthermore, 
Shime et al113 demonstrated that lactate increases the transcription 
and secretion of IL-23, a tumor-promoting cytokine involved in the 
generation of Th17 cells, in human monocytes/macrophages. In ad-
dition, acidification of the tumor microenvironment can be sensed 
by TAMs via GPR43 resulting in macrophage polarization toward a 
tumor-promoting phenotype.114 Interestingly, TAMs are not only a 
target of the tumor-induced lactate acidosis but are also important 
producers of lactate. Seth and colleagues showed that TAMs express 
LDH-A, secrete lactate in the tumor microenvironment and myeloid 
specific deletion of LDH-A supported T cell anti-tumor response 
and reduced tumor growth.17 Yet another player might contribute to 
tumor lactate acidosis, as it has been demonstrated that glycolytic 
CAFs release lactate which reduced the percentage of the anti-tu-
moral Th1 subset, and increased regulatory T cells (Treg) cells in a 
prostate cancer model, indicating an important immunosuppressive 
role of the reverse Warburg effect.115
Therefore, targeting the Warburg effect in cancer and stromal 
cells, such as via LDH-A inhibition could be an effective strategy to 
reactivate the adaptive anti-tumor immune response.17 It is widely 
established that tumor-derived lactic acid and acidification impair 
T and NK cell function.14,84,112,116,117 NK cells from Ldha-depleted 
tumors show improved cytolytic function and lactate treatment of 
NK cells inhibits cytolytic function in vitro. Furthermore, LDH-A 
expression in melanoma biopsies correlated with T cell activity and 
LDH-A associated lactic acid production and acidification impaired 
IFNγ expression in tumor-infiltrating T cells and NK cells, thereby in-
hibiting tumor immunosurveillance and promoting tumor growth.84 
A relation of the tumor metabolic status with an anti-tumor T cell 
response has been observed in several entities and prominent exam-
ples are summarized in Table 1.
But what is the underlying mechanism for the profound impair-
ment of immune cell function through lactic acidosis? Stimulation 
of monocytes and lymphoid cells results in accelerated glycolysis 
which is crucial for their function. Glucose transporters, glycolytic 
enzymes, and lactate transporters such as MCT1 and MCT4 are up-
regulated to support glycolytic activity in immune cells.36,39,118-120 To 
assure the continuation of glycolysis, protons and lactate molecules 
have to be exported by MCTs following a concentration gradient. 
An inauspicious lactic acid gradient between the extracellular tumor 
milieu and the cytoplasm of immune cells leads to uptake of lactate 
and protons in immune cells, lowering the intracellular pH and limit-
ing the glycolytic flux which results in impaired monocyte and T cell 
function.14,40,121 On the molecular level, treatment of T cells with 
lactic acid prevented TCR-triggered phosphorylation of JNK, c-Jun, 
p38, and NFAT activation and lowered ATP levels causing a meta-
bolic catastrophe.84,122 A very recent study in tumor cell lines and 
murine macrophages shows that intracellular lactate, either endog-
enously produced or taken up, can directly bind to histone lysine 
residues and trigger epigenetic modifications that guide macrophage 
polarization.123 This study raises the question, whether lactate has 
yet unknown direct effects on gene expression or post-translational 
modifications of proteins. Besides lactate production and acidifi-
cation, accelerated glucose metabolism of malignant and stromal 
cells can result in a nutrient competition in the tumor environment. 
TA B L E  1   The relation of tumor glucose metabolism and anti-tumor T cell response
Tumor entity
Metabolic feature
High tumor glucose uptake/
metabolism (MeTS 3/4)
High tumor-stroma glucose 
metabolism (MeTS 2)
OXPHOS-dominant 
tumor (MeTS 1) Ref.
Melanoma Decreased T cell activity, inferior 
response to checkpoint blockade
 Good response to 
checkpoint blockadea 
84,119,173,175
Renal cell carcinoma Lower T cell infiltration, inferior 
response to checkpoint blockade
  24,172
Colon cancer Lower CD8 T cell infiltration   25
Head and neck 
squamous cell 
carcinoma
Lower CD8 T cell infiltration   26
Lung squamous cell 
carcinoma
Lower CD8 T cell infiltration   26
Lung adenocarcinoma  Lower T cell infiltration  55
Lung carcinoma  Impaired anti-tumor T cell response  17
Prostate cancer  Reduced anti-tumoral Th1 cells  115
aA contradictory finding by Najjar et al174 who found high tumor OXPHOS as a barrier to checkpoint blockade. 
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A metabolic interplay between tumors and immune cells has been 
demonstrated in murine models.34,124 These studies suggested that 
a glucose poor environment limits glycolysis of tumor-infiltrating T 
cells which suppresses effector functions. In contrast, Tregs seem 
to be more resistant to the metabolic challenges in the tumor en-
vironment. Angelin et al125 reported that Tregs can maintain their 
immunosuppressive function even in low-glucose, high-lactate en-
vironments based on their metabolic status and reduced glycolytic 
activity. The transcription factor Foxp3 downregulates MYC and gly-
colysis and induces oxidative phosphorylation. In addition, enforced 
glycolysis decreases the immunosuppressive function of Tregs and 
conversely, expression of Foxp3 opposes mTORC1 mediated met-
abolic switch toward glycolysis.44 These metabolic adaptations in 
Tregs could be a physiological mechanism of peripheral tolerance 
in tissues with low-glucose and high-lactate concentrations, such 
as the intestinal tract or ischemic tissues. These sites require a cer-
tain level of immune tolerance, avoiding unwanted reactions against 
self-antigens or commensal bacteria. Even though glucose levels are 
decreased in multiple tumor types analyzed up to now, the average 
glucose level rarely fall below 1 mmol/L.84,126 Intriguingly, these lev-
els will most likely not limit key T cell effector functions.127-129 In rec-
tal carcinomas and ovarian peritoneal metastases, however, Walenta 
et al126 reported glucose levels below 1 mmol/L in over 65% and 
40%, respectively, of all tumors, indicating that specifically in these 
tumor entities nutrient competition may play an important role.
In conclusion, these data clearly demonstrate that tumor-derived 
lactate and acidification have a broad spectrum of effects and reg-
ulate tumor growth and metastasis at different levels, for example, 
via promotion of cell motility and evasion, modulation of tumor-as-
sociated stromal fibroblasts, stimulation of endothelial cells and sup-
pression of anti-tumor immune cells.
6  | L AC TATE ACCUMUL ATION AND 
ACIDIFIC ATION—FUNDAMENTAL 
IMMUNOSUPPRESSIVE STR ATEGIES
Apart from their role in the tumor environment, lactate accumula-
tion and acidification are evolutionary conserved phenomena that 
occur in localized inflammation. It has been known for decades 
that the synovial fluid of patients with arthritis contains high-
lactate concentrations and that synovial fluid acidosis positively 
correlates with joint destruction.130 Gobelet et al described lac-
tate concentrations up to 23 mmol/L (a more than 20-fold increase 
compared to serum) in non-gonococcal septic arthritis. Lactate 
levels in synovial fluid from patients with a chronic inflammation, 
such as rheumatoid arthritis (RA) were around 6 mmol/L in this 
study.131 Three major factors have been proposed to induce a local 
lactic acidosis in inflamed tissues: (a) tissue hypoxia through dam-
aged small blood vessels, (b) increased metabolic activity of leuko-
cytes, and (c) the accumulation of short-chain fatty acids produced 
by bacteria.132,133 Moreover, high LDH activity has been described 
in the synovial fluid of RA patients with a shift from LDH1 and 
LDH2 isoforms to the glycolysis-associated isoforms LDH4 and 
LDH5.134 Lactate is then taken up via the sodium-lactate trans-
porters in T cells thereby leading to entrapment and functional 
changes that drive chronic inflammation.135 Lactate uptake also 
results in increased IL-17 production via PKM2/STAT3 signaling 
and enhanced fatty acid synthesis.136 Interestingly, the presence 
of synovial lactate has also been proposed as a fast clinical diag-
nostic tool to identify patients with septic arthritis.137,138
Long known and widely accepted, the acidification of the skin 
represents a pillar of its barrier function. It has been observed that 
low pH of the skin regulates its permeability, improves the integrity 
and cohesion of stratum corneum (SC), and increases anti-microbial 
defenses.139 Interestingly, Hatano et al reported that acidification 
inhibits infiltration of Th2 cells into the skin. Furthermore, low pH 
prevents the production of IL-1α and TNF, indicating immunosup-
pression.140 These observations lead to preclinical and clinical trials 
that aimed to lower skin pH and induced acidification of SC was able 
to delay progression of atopic dermatitis.141 Furthermore, systemic 
acidosis can affect the inflammatory milieu of the skin; Tzeng et al142 
induced systemic acidosis through hypercapnia, leading to an im-
proved survival of skin allografts in mice. This was mediated through 
a reduction of pro-inflammatory cytokines, decreased immune cell 
infiltration and NF-kB activation.
Thus, lactate accumulation and local lactic acidosis are evolu-
tionary conserved mechanisms that both prevent an infection and 
accompany the inflammation. High lactate and low pH in inflamed 
tissues might be beneficial, such as through being a natural “anti-
septic” or through a confinement of T cells at the inflammatory site, 
thus supporting a clearance of the pathogen. At the same time, they 
might do harm by inhibiting cytolytic function of CD8 T cells or in-
ducing a Th17 phenotype in CD4 T cells.
7  | TARGETING THE WARBURG EFFEC T 
FOR TUMOR THER APY AND IMMUNE 
AC TIVATION
It appears that tumors exploit metabolic pathways that are universal 
and can be beneficial for the resolution of inflammation in a non-
malignant setting, as discussed above. The dramatic increase in gly-
colytic activity in MeTS4 tumors as well as their dependency on the 
Warburg effect appears to provide an ideal target for therapy. Even 
though a direct metabolic modulation of tumors is challenging, sev-
eral preclinical and clinical studies addressed the metabolic vulner-
ability of tumors and identified promising targets.
Highly accelerated glycolytic activity was regarded a unique 
feature of tumor cells for a long time, but strategies to target the 
Warburg phenotype were sparse. Beside some early trials admin-
istering the glucose analogue 2-deoxy-glucose to patients,143,144 
no major efforts were made. The situation, however, has changed 
and in the meantime there is a myriad of drugs available either 
to block the glycolytic pathway itself or to reverse acidity in the 
tumor microenvironment, extensively reviewed by Feichtinger 
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et al.145 Among those drugs, 3-bromo-pyruvate, inhibiting glycer-
aldehyde 3-phosphate dehydrogenase,146 gained great attention 
due to convincing results in preclinical studies, but enthusiasm was 
dampened as specificity and safety concerns were raised.147 One 
of the most common structures to target the Warburg effect is the 
LDH-A. More than 1000 FDA approved drugs against LDH-A are 
now available; however, only a few of them are tested in preclinical 
or clinical trials. Some of them lack specificity, show side effects 
(reviewed in 148), or their clinical use is hampered by a low potency. 
Some examples include gossypol,149-151 its analogue FX11,152 ox-
amate or quinolone-3-sulfonamide.153 Others showed promising 
results in preclinical studies, but are not yet tested in clinical trials, 
such as the pyrazol-based inhibitor GNE-140.154,155 Surprisingly, 
recent studies show anti-glycolytic properties of vitamin C.156,157 
Nevertheless, targeting LDH-A alone might not be sufficient to 
significantly reduce lactate secretion in certain cancers as only a 
double knock out of both isoforms LDH-A and LDH-B resulted in 
a complete block in lactate secretion.158 Finally, drugs targeting 
MCT1 and MCT4 are currently investigated in preclinical stud-
ies159,160 with the MCT1 inhibitor AZD3956 being tested in a clin-
ical trial (NCT01791595). Beside these more specific inhibitors, 
the well-known non-steroidal anti-inflammatory drug diclofenac 
and its derivative lumiracoxib block both MCT1 and MCT4119,161 
and reduce lactate secretion. In addition, immune-modulatory 
drugs such as lenalidomide act on these transporters by disrupt-
ing the MCT-CD147 axis, which is essential for their membrane 
expression.162
A highly glycolytic tumor metabolism is also associated with re-
sistance to conventional therapies. Such Warburg effect-mediated 
therapy resistance were observed with the proteasome inhibitor 
bortezomib in multiple myeloma cells, carboplatin in non-small-cell 
lung163 and paclitaxel in lung cancer cells.164 Furthermore, a study 
by Zhao et al revealed that heat shock factor 1 and LDH-A drive gly-
colysis and induce resistance to trastuzumab, an anti-HER2 receptor 
antibody in breast cancer cells.165 Mechanisms of how tumor gly-
colysis mediates therapy resistance are not completely elucidated, 
but this phenomenon has repeatedly been linked to the activity of 
P-glycoprotein (P-gp), which actively pumps cytotoxic drugs such as 
doxorubicin and paclitaxel out of the cell and the activity of P-gp 
increases in hypoxia and acidosis.166 Another mechanism how tu-
mors benefit from acidosis, and which is frequently neglected, is 
the “ion trapping”—a process where charged compounds such as 
chemotherapeutics cannot pass a cellular membrane due to de-
creased permeability.167 Therefore, a combination of anti-glycolytic 
therapy and acidification reversal might strengthen the therapeu-
tic outcome and this approach is being currently tested in clinical 
trials (NCT01748500, NCT01069081, NCT01163903). Whether 
using conventional or experimental approaches to target cancer 
cells, tumor stroma should not be neglected; in several entities, the 
role of stromal cells, such as CAFs, has been established in ther-
apy resistance. Several approaches have been proposed to target 
CAFs. For example, pharmacological targeting by sibrotuzumab and 
pirfenidonen was able to prevent CAFs activation and thus tumor 
growth.168,169 Other strategies for stromal cell targeting were sum-
marized by Dykes et al.170
Given that the accumulation of lactate and acidification block the 
anti-tumor function of T and NK cells and foster the differentiation 
and activity of immune cell populations supporting tumor growth 
such as Tregs or MDSCs, the Warburg effect limits the success of 
immunotherapeutic approaches. In line, the efficacy of adoptive T 
cell transfer can be limited due to increased tumor glycolytic activ-
ity.171 Furthermore, first studies in humans show a correlation be-
tween a high glycolytic activity in tumors and a low response rate 
to checkpoint blockade.119,172 Accordingly, good response to immu-
notherapy was associated with enriched mitochondrial metabolism 
in melanoma patients.173 Surprisingly, the opposite finding was re-
ported regarding PD-1 blockade in a melanoma study showing that 
tumor oxygen consumption was associated with T cell exhaustion 
and progression under checkpoint blockade.174 Nevertheless, the 
efficacy of checkpoint blockade was improved by LDH suppression 
in murine tumors.119,175,176 Glycolytic tumor stroma (equivalent to 
MeTS2a) might drive cancer progression even in the presence of 
non-glycolytic tumor cells (Figure 1). In line with the work of Seth 
et al17 inhibition of pyruvate dehydrogenase kinase by dichloroac-
etate targeted macrophages and decreased T cell and NK cell sup-
pression in tumors.177
As the Warburg phenotype is not specific for tumor cells or 
tumor-promoting stromal cells, but a common feature of prolifer-
ating and activated immune cells, such as effector T cells and NK 
cells,34,35,37,38,178,179 the application of glycolytic inhibitors could 
exert side effects on the immune system. Buffering, therefore, 
might be an alternative strategy to reduce the negative effects of 
tumor acidification not interfering with immune cell activation.104,180 
Accordingly, different buffering approaches such as the administra-
tion of bicarbonate or proton pump inhibitors (PPIs) promoted im-
munotherapy.181-183 Moreover, Vishvakarma and collegues showed 
that the application of PPIs resulted in an enhanced recruitment of 
M1 macrophages and shifted the cytokine profile toward tumor cy-
totoxic cytokines. Finally, this study showed that macrophages iso-
lated from PPI treated tumors, which were adoptively transferred 
in tumor-bearing mice, showed superior capacity to control tumor 
growth.184
Glycolytic restriction might not affect all immune cell popula-
tions to the same extent; it has been shown that under low-glu-
cose conditions, T cells show a remarkable flexibility and while 
proliferation decreases, effector functions are preserved.127-129,185 
Therefore, glycolytic inhibitors might be beneficial even in a tumor 
setting. In line, lenalidomide has been shown to promote IL-2 ex-
pression in T cells.186 Notably, the response to adoptive T cell 
transfer was improved by the application of the LDH-A inhibitor 
GNE-140.171 Finally, we investigated the effect of diclofenac and 
lumiracoxib in vitro and in vivo. Lowering glycolytic activity re-
duced proliferation of T cells but effector functions were not al-
tered and NSAIDs supported checkpoint inhibition in vitro and in 
vivo. Furthermore, it has been proposed by different studies that 
lowering glycolytic activity but supporting mitochondrial fitness 
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and enhancing fatty acid metabolism in T cells might strengthen 
their anti-tumor immune response.187-191 This view is further sup-
ported by a recent study of Ma et al showing that in contrast to 
in vitro activated T cells which display hallmarks of Warburg me-
tabolism, physiologically activated CD8 T cells displayed greater 
rates of oxidative metabolism in vivo, as assessed by 13C-glucose 
infusion techniques in an infection model.192
8  | CONCLUSION AND OUTLOOK
Almost 100 years after its first description, many new tumor-
promoting aspects of the Warburg effect have been discovered 
beside its classical role in energy generation. The “waste products” 
lactate and acidification have profound impact on tumor angio-
genesis, migration and last but not least on the anti-tumor immune 
response. Importantly, not only tumor cells but also activated stro-
mal cells such as fibroblasts and macrophages can produce lactate 
in the so called “Reverse Warburg effect,” contributing to tumor 
lactic acidosis and shaping the immune response even in tumors 
with oxidative metabolism in malignant cells. Therefore, the im-
munosuppressive microenvironment does not solely depend on 
the metabolic phenotype of tumor cells but also on the composi-
tion and activation status of stromal cells. Based on the impor-
tant role of T cell infiltration for patient outcome, we suggest a 
metabolic-tumor-stroma score (MeTS) to determine the likelihood 
of a successful anti-tumor immune response. We define four 
major metabolic tumor types (Figure 1): (MeTS1) OXPHOS tumors, 
(MeTS2) a reverse Warburg type with OXPHOS in tumor cells but 
high glycolysis in stromal cells, (MeTS3) a mixed type with glyco-
lysis and OXPHOS, and (MeTS4) a highly glycolytic Warburg type. 
MeTS1 tumors may show the best response to immunotherapy 
without further intervention, MeTS2 tumors could benefit from 
stroma-targeted approaches, while in MeTS3-MeTS4 tumors with 
increasing levels of lactate and acidification, targeting glycolysis 
and/or stromal cells might be essential to allow an effective im-
mune response, which is of special importance in the context of 
cancer immunotherapy.
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